^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | erfonrilimab (KN046) (PD-L1 inhibitor, CTLA4 inhibitor) + anbenitamab (KN026) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
KN026 Combined With KN046 in Subjects With HER2 Positive Solid Tumor
Excerpt:
...- Histologically or cytologically documented advanced HER2 positive solid tumor...
Trial ID:
Source:
Title:
Preliminary safety and efficacy results of KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) in combination with KN026 (a HER2-targeted bispecific antibody) in patients with metastatic HER2-positive breast cancer: A phase II trial
Published date:
10/09/2021
Excerpt:
The ORR was 50.0% (11 of 22, 95% CI: 28.2-71.8), and one patient achieved complete response (CR). And the disease control rate (DCR) was 81.8% (18 of 22, 95% CI 59.7-94.8). The median progression-free survival (PFS) was 5.6 (95%CI 2.5-not reached) months....The combination of KN046 and KN026, as a chemo free regimen, has shown favorable clinical efficacy with manageable side effects in heavily pre-treated patients with metastatic HER2-positive breast cancer.
